Windtree Therapeutics, Inc. Non-operating Interest Expenses

Non-operating Interest Expenses of WINT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Non-operating Interest Expenses growth rates and interactive chart. Interest expense that is usually non-recurring and not tied to a company's operations. It is stated separately on the income statement to differentiate it from interest expenses.


Highlights and Quick Summary

  • Non-operating Interest Expenses for the quarter ending June 29, 2020 was $31 Thousand (a -29.55% decrease compared to previous quarter)
  • Year-over-year quarterly Non-operating Interest Expenses decreased by -70.48%
  • Annual Non-operating Interest Expenses for 2019 was $495 Thousand (a -64.87% decrease from previous year)
  • Annual Non-operating Interest Expenses for 2018 was $1.41 Million (a -24.37% decrease from previous year)
  • Annual Non-operating Interest Expenses for 2017 was $1.86 Million (a -26.01% decrease from previous year)
  • Twelve month Non-operating Interest Expenses ending June 29, 2020 was $317 Thousand (a -21.34% decrease compared to previous quarter)
  • Twelve month trailing Non-operating Interest Expenses decreased by -71.82% year-over-year
Trailing Non-operating Interest Expenses for the last four month:
29 Jun '20 30 Mar '20 30 Dec '19 29 Sep '19
$317 Thousand $403 Thousand $495 Thousand $1.13 Million
Visit stockrow.com/WINT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Non-operating Interest Expenses of Windtree Therapeutics, Inc.

Most recent Non-operating Interest Expensesof WINT including historical data for past 10 years.

Interactive Chart of Non-operating Interest Expenses of Windtree Therapeutics, Inc.

Windtree Therapeutics, Inc. Non-operating Interest Expenses for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $0.03 $0.04
2019 $0.14 $0.11 $0.12 $0.14 $0.5
2018 $0.77 $0.46 $0.09 $0.09 $1.41
2017 $-0.02 $0.65 $0.62 $0.61 $1.86
2016 $0.61 $0.65 $0.64 $0.62 $2.52
2015 $0.62 $1.5 $1.26 $1.21 $4.58
2014 $1.2 $1.17 $1.13 $1.09 $4.6
2013 $0.6 $0.35 $0.34 $0.18 $1.47
2012 $0.05 $0.0 $0.0 $0.0 $0.06
2011 $0.0 $0.01 $0.01 $0.01 $0.03
2010 $0.01 $0.02 $0.09 $0.24 $0.36

Business Profile of Windtree Therapeutics, Inc.

Sector: Medical
Industry: Drugs
Windtree Therapeutics, Inc., a biotechnology and medical device company, engages in the research and development of products that focus on acute pulmonary and cardiovascular diseases. Its four lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome (RDS) in premature infants; lyophilized KL4 surfactant for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania.